Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04449874 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Genentech.
- Active
- Registry status
- Phase 1
- Development phase
- 498
- Enrollment target
- 20
- Study locations
NCT04449874: Active Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Genentech.
NCT04449874 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is active but no longer recruiting, run by Genentech. The registered enrollment target is 498 participants, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04449874, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 498 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Primary Outcome
Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Cetuximab
- DRUG Erlotinib
- DRUG GDC-6036
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCSD Moores Cancer Center - La Jolla
- Chao Family Comprehensive Cancer Center UCI - Orange
Other
- UZ Antwerpen - Edegem
- CHU de Liège - Liège
- AZ St Maarten Campus Leopoldstr - Mechelen
Pennsylvania
- Abramson Cancer Center - Philadelphia
- UPMC - Hillman Cancer Center - Pittsburgh
New South Wales
- St Vincent's Hospital Sydney - Darlinghurst
- Slade Health Inward goods - Mount Kuring-Gai
Victoria
- Peter MacCallum Cancer Center - Melbourne
- Alfred Health - Melbourne
Connecticut
- Yale Cancer Center - New Haven
Massachusetts
- Dana Farber Cancer Institute - Boston
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What the registry record for NCT04449874 still lists
NCT04449874 is an interventional study that assigns participants to a tested intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (24% lower).
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04449874 names 20 study sites across 13 states, led by California, Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04449874 about?
NCT04449874 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation". This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
What is the current status of trial NCT04449874?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 498 participants. The study started on 2020-07-29. Estimated completion is 2027-12-31.
What conditions does trial NCT04449874 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors.
What interventions are being tested in trial NCT04449874?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Cetuximab (DRUG), Erlotinib (DRUG), GDC-6036 (DRUG).
Who is sponsoring clinical trial NCT04449874?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04449874 being conducted?
This trial has 20 study locations across California, Connecticut, Massachusetts, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04449874's enrollment target sits among peer trials
498 78th of 454 higher than 377 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI